Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Baird, S
2012;11:CD008394
Phase 2: Market Creation at Scale Novo Nordisk didnt just innovateit scaled demand aggressively: Positioned GLP-1 as a dual-solution drug (diabetes + weight loss) Expanded into non-diabetic populations seeking weight management Invested heavily in manufacturing and global supply chains Built direct-to-consumer channels to improve access By 2025: GLP-1 drugs became the primary growth driver for the company Novo Nordisk held a dominant share in the GLP-1 market Demand surged globally, driven by rising obesity and diabetes rates The broader GLP-1 market is now expected to grow at ~14% CAGR, driven by lifestyle diseases and expanding use cases
Researchers looked at nearly 22,000 patients and compared the hospital records of those on GLP-1 drugs with those of a preventive migraine drug to see which group went to the hospital less for migraine-related issues
US$ 22.85
US$ 24.43
US$ 23.67
US$ 21.66
US$ 21.26
